DOCSLIB.ORG

Abstract Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Book 27 March 2020 Volume 27 Supplement 1 S1 Volume 27 Volume Supplement 1 A1–A232 Pages EUROPEAN JOURNAL OF HOSPITAL PHARMACY OF HOSPITAL JOURNAL EUROPEAN ABSTRACT BOOK 25th EAHP Congress 25th–27th March 2020 Gothenburg, Sweden March 2020 March CALL FOR ABSTRACTS - 2021 26th Congress of the EAHP, 24-26 March 2021, Vienna, Austria Abstract submission opens 1st August, 2020! Original contributions from all fields of hospital pharmacy are encouraged and welcomed for poster presentation. Deadline for submission: 15th October 2020 During the review process, the award nominees will be selected and the presenting author of the nominated abstracts will be invited to give an oral presentation after which the final judging will take place. Please be sure to provide an email address which will not be blocked by spam servers so that EAHP may notify you for modifications and nominations. (Abstracts may be submitted through the EAHP web site’s online submission page.) IMPORTANT NOTE: The online submission form does not recognise some symbols from certain keyboards. Therefore, please proof your abstract after it has been entered into the system and before your final submission. Please visit the EAHP web site at http://www.eahp.eu/congresses/abstract to view the guidelines and to submit abstracts for the Vienna Congress 2021. Abstracts must be entered into the system by section according to the guidelines. There will be 5 sections: Background - Aim and objectives - Material and methods - Results - Conclusion All abstracts must be linked to the European Statements on Hospital Pharmacy: Section 1: Introductory Statements and Governance Section 2: Selection, Procurement and Distribution Section 3: Production and Compounding Section 4: Clinical Pharmacy Services Section 5: Patient Safety and Quality Assurance Section 6: Education and Research Contents Volume 27 Supplement 1 | EJHP March 2020 Abstracts from the EAHP 2020 Congress A1 Section 1: Introductory Statements and A150 Section 5: Patient Safety and Quality Governance Assurance A9 Section 2: Selection, Procurement and A205 Section 6: Education and Research Distribution A215 National Poster Prize Winners A22 Section 3: Production and Compounding A222 Author Index A47 Section 4: Clinical Pharmacy Services $:$5'120,1((6 3UHVHQWDWLRQVRQ:HGQHVGD\0DUFK±5220) 7LPH 3RVWHUQXPEHU $ZDUGQRPLQHHRUDOSUHVHQWDWLRQV 3UHVHQWLQJDXWKRU +2:08&+'2(6)$/6,),('0(',&,1(6',5(&7,9($&78$//< Section 2 &2676"'(7$,/('&267(9$/8$7,212)6(5,$/,6$7,21,1 10:33 $)LWWOHU 2SPD-023 $5(35(6(17$7,9(6$03/(2)+81*$5,$1+263,7$/ 3+$50$&,(6 Section 3 $872/2*2867,668($'+(6,9(,123+7+$/02/2*,&$/ 10:41 6%HULVD 3PC-032 685*(5< Section 4 '(9(/230(172)$%(/*,$1&/$66,),&$7,216<67(0)25 10:49 3-&RUWRRV 4CPS-168 &/,1,&$/3+$50$&<$&7,9,7,(6 Section 4 &267())(&7,9(1(66$1$/<6,62)0(523(1(0'26( 10:57 $2UWHJD 4CPS-045 237,0,6$7,21,1&5,7,&$/3$7,(176 5,6.)$&7256$662&,$7(':,7+5($'0,66,21727+( Section 4 (0(5*(1&<'(3$570(17,13$7,(176:,7+35(9,286 11:05 //ySH]9LQDUGHOO 4CPS-008 *$6752,17(67,1$/+$(0255+$*(6(&21'$5<7225$/ $17,&2$*8/$177+(5$3< 81'(5'26,1*:,7++,*+'26(3,3(5$&,//,17$=2%$&7$0 Section 4 $'0,1,67(5('9,$&217,18286,1)86,21,12873$7,(17 11:13 &4XLQWHQV 4CPS-049 3$5(17(5$/$17,0,&52%,$/7+(5$3<$67$%,/,7<25 9,6&26,7<352%/(0" )$&,/,7$7256$1'%$55,(56723(5)250,1* Section 4 &2035(+(16,9(0(',&$7,215(9,(:6$1')2//2:83,1 11:21 8*LOOHVSLH 4CPS-174 2/'(5+263,7$/,6('3$7,(176%<08/7,352)(66,21$/ :$5'7($06,1&/8',1*$&/,1,&$/3+$50$&,67 Section 4 7+(81'(55(3257,1*5$7($6$3+$50$&29,*,/$1&( 11:29 352&(66,1',&$725,1$&2035(+(16,9(&$1&(5 (2PRGHR6DOq 4CPS-194 &(175( $6$)(+$1'/,1*+$=$5'286'58*6675$7(*<72 Section 4 ,03529(7+(6$)(7<2)+($/7+352)(66,21$/6 11:37 ,&DxDPDUHV2UELV 4CPS-164 5('8&,1*(;32685(%<0(',&$/35(6&5,37,215(9,(:,1 1856,1*+20(6 Section 5 $1$/<6,62)'58*,17(5$&7,216%(7:((125$/ 11:45 È1DUULOORV0RUD]D 5PSQ-048 $17,1(23/$67,&$*(176$1'&21&855(170(',&$7,216 SYNERGY SATELLITE EVENT THE EAHP INVITES YOU TO ATTEND THE 2020 SYNERGY SATELLITE SESSION: Hospital pharmacists making the difference Biologics in cancer care have enhanced the therapeutic options With the patents set to expire for a number of medications, for clinicians in the management of oncologic therapy. Monoclonal biosimilars therapeutic proteins offer the potential to increase antibodies (mAbs) are employed as targeted treatment and also access to therapies and reEuDe cancer costs for patients to resolve therapy-related hematologic defi ciencies. and healthcare systems. Sponsored by an educational grant from Amgen Wednesday, 25 March 2020 25th Congress of the EAHP 25-27 March 2020 Gothenburg, Sweden 12:00 to 13:30, Hall C Facilitator Despoina Makridaki Presenters Oncology Biosimilars - ongoing challenges for hospital pharmacists Antonio Melo Gouveia Budget impact and cost-effectiveness of oncology biosimilars Steven Simoens* Biosimilars in Oncology: Healthcare and clinical considerations Ioannis Boukovinas* CONTACT US | [email protected] ACPE UAN: 0475-0000-20-005-L04-P. A knowledge based activity. th The European Association of Hospital Pharmacists (EAHP) is accredited by the EAHP CONGRESS Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education SYNERGY SATELLITE EVENT THE EAHP INVITES YOU TO ATTEND THE 2020 SYNERGY SATELLITE SESSION: 25th Congress of the EAHP 25-27 March 2020 Gothenburg, Sweden The Hospital Pharmacist can balance the antithrombotic benefit of the DOAC with its bleeding risk by recommending the appropriate dose of DOACs to physicians according to the patients’ characteristics. The Hospital Pharmacist as part of an antithrombotic stewardship programme needs to ensure adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications. The Hospital Pharmacist’s role in antithrombotic stewardship SPONSORED BY AN EDUCATIONAL GRANT FROM BAYER Facilitator Virgina Silvari Wednesday, 25th March 2020 14.45 to 16.15 room H1 Thursday, 26th March 2020 Presenters Minimising bleeding Antithrombotic stewardship: the proof of risk associated with 08.45 to 10.15 room H1 the pudding... anticoagulation use Paul Wright Patricia Van Den Bemt CONTACT US | [email protected] ACPE UAN: 0475-0000-20-006-L04-P. A knowledge based activity. th The European Association of Hospital Pharmacists (EAHP) is accredited by the EAHP CONGRESS Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education Abstracts Section 1: Introductory Statements and 1ISG-002 BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST Governance ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS 1ISG-001 CAN RIVAROXABAN BECOME COST SAVING 1N Sagaria*, 2D Mengato, 1I Corbucci, 1G Felluga, 2G Morandell, 2ATavella.1School of COMPARED WITH VITAMIN K ANTAGONISTS IN THE Hospital Pharmacy, Department of Pharmaceutical Sciences University of Padova, Padova, TREATMENT OF PATIENTS WITH NON-VALVULAR Italy; 2Bolzano General Hospital, Hospital Pharmacy Department, Bolzano, Italy ATRIAL FIBRILLATION IN FRANCE? 10.1136/ejhpharm-2020-eahpconf.2 1SRobert*,2F Vincent, 3S Vengadessane. 1Chru Nancy, Pharmacy, Vandoeuvre Les Nancy, 2 3 France; Hospices Civils De Lyon, Pharmacie, Lyon, France; Université Paris Descartes, Background and importance The introduction of the first bio- Faculté De Pharmacie De Paris, Paris, France logical drugs has led to a new era for patients. Moreover, the recent arrival of biosimilars has guaranteed effectiveness 10.1136/ejhpharm-2020-eahpconf.1 at a more sustainable cost. We compared the recently Background and importance Non-valvular atrial fibrillation approved biological drugs with biosimilars and older biologi- (NVAF) affects 750 000 people in France and is associated cal molecules, using a new cost effectiveness analysis with significant morbidity, use of healthcare resources and approach. costs. The randomised controlled trial ROCKET-AF demon- Aim and objectives To compare the long term therapy cost strated that rivaroxaban is an efficacious alternative to war- and cost effectiveness of biological systemic therapies for treat- farin in patients with NVAF. The new oral anticoagulants ing patients with moderate to severe plaque psoriasis. (NOAC) appear to have an acceptable cost effectiveness Material and methods We collected therapy costs from our ratio in France. But is it possible that rivaroxaban could internal hospital database. We reported the purchase price, remain cost effective with the introduction of generic including any discounts. Efficacy data, measured with the PASI drugs? index, for 12/16 weeks, was obtained from a recent meta- Aim and objectives To determine the price threshold for rivar- analysis by Sawyer et al. We calculated the long term costs by oxaban to become cost effective compared with vitamin K multiplying the monthly cost for a single patient, including antagonists (VKAs) in the treatment of NVAF, using real the induction phase. Our cost effectiveness analysis was per- world evidence and from a French payer perspective. formed by a correlation analysis between efficacy and the cost Material and methods The annual cost differences associated of therapy for the 12/16 weeks of treatment. We calculated, with rivaroxaban use compared with VKAs among NVAF for each molecule at a different PASI, a correlation index (R) patients were estimated. Clinical events reflecting the efficacy to investigate if a correlation between cost and efficacy could and safety of the drugs were converted into costs. Drugs costs be established. and VKA monitoring were added to obtain a total cost. Cost Results Cost analysis of the first year and the first 3 years of differences were then calculated with a price of rivaroxaban therapy showed how the introduction of biosimilar drugs reduced by: 20% (reduction in the price of the brand name greatly lowered global expenditure.
Load more

Recommended publications
  • How to Fortify Beverages with Calcium by Dr
    Ingredients How to Fortify Beverages With Calcium by Dr. Gerhard Gerstner Along with current developments of the overall functional foods market, the use of minerals and especially calcium salts is expected to exhibit strong growth rates. In contrary to other functional ingredients, calcium is widely known as being beneficial for human health and there is no need to explain its nutritional ad- vantages to the customer. According to Leatherhead International, future trends include growing consumer concern regarding osteoporosis and bone health, leading to increased sales of calcium salts. The con- observation is seen as being one of tinuous market growth drives mineral the main factors causing osteo- Common calium sources salt suppliers to offer not only one porosis 2 .As a consequence, national for beverage fortification product but rather a range of different authorities all over the world have calcium salts and granulations to be recently reconsidered recommend- Table 1 shows a typical range of able to tune them to industrial cus- ations in order to take remedial calcium fortified beverages which tomers’ applications. This article measures against calcium deficiency have been seen in European and US discusses important nutritional, and accordingly, to reduce the risk of supermarkets recently. Practically technological as well as economical osteoporosis. In this respect, the US every type of beverage such as aspects of calcium in beverages with National Institute of Health (NIH) has mineral water, soy milk, energy drink, a focus on our company’s products increased the amounts of optimal nectar or juice does have a fortified Tricalcium Citrate, Calcium Gluconate daily calcium intake and defined product line already.
    [Show full text]
  • EMBASE Find Quick, Relevant Answers to Your Biomedical Questions
    EMBASE Find quick, relevant answers to your biomedical questions Piotr Golkiewicz Solution Sales Manager Life Sciences Central and Eastern Europe and Russia Embase® is a registered trademark of Elsevier BV. WHAT IS EMBASE? THE WORLD’S MOST COMPREHENSIVE BIOMEDICAL RESEARCH TOOL Reliable and authoritative content to help the drug and drug-related research community advance new biomedical and pharmaceutical discoveries. Confidence Find all relevant articles that may not otherwise be found by using alternative databases Deep Biomedical Indexing All relevant, up-to-date, biomedical information from the research literature Precise Retrieval Deep and focused research using the most powerful retrieval tools 2 HOW EMBASE DELIVERS VALUE ...by including literature and Conference Scientific In Press We make sure you information resources in a proceedings Journals (unpublished) don’t miss any timely manner biomedical literature ...by reading full-text to The only close identify drugs, diseases, Deep indexing using own taxonomy alternative is adverse affects, clinical (EMTREE) reading trials, drug trade names etc. all the articles ...by enabling advanced search filters to drill down a Very powerful Good precision and comprehensive search to a recall balance relevant and manageable record Search Environment set ...by allowing users to automate Automation and searching and result management documentation E-mail Alerting API Interoperability 3 EMBASE CONTENT 4 EMBASE IS AS COMPREHENSIVE AS POSSIBLE SOURCE TEXT MINING EMBASE SCOPUS Effort / tools required / tools Effort PUBMED GOOGLE 0 % 50 % 100 % Percentage of relevant articles retrieved 5 COMPREHENSIVE CONTENT COVERAGE ON AVERAGE >5000 RECORDS ADDED EACH WORKDAY! Embase: Now covers over 8,400 journals Indexed at Embase (over 5,700 titles) Indexed by MEDLINE (e.g.
    [Show full text]
  • Disseminated Fusarium Infections in Acute Lymphoblastic Leukemia
    CASE REPORT Serbian Journal of Dermatology and Venereology 2018; 10 (2): 43-46 DOI: 10.2478/sjdv-2018-0007 Disseminated Fusarium Infections in Acute Lymphoblastic Leukemia Morgan COVINGTON1, Juliana GAO2, Farah ABDULLA3, Vesna PETRONIĆ ROSIĆ2 1Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA 2Section of Dermatology, Department of Medicine, The University of Chicago, Chicago, IL, USA 3Division of Dermatology, City of Hope, Duarte, CA, USA *Correspondence: Vesna Petronić Rosić, E-mail: [email protected] UDC 616.992:616.155.392 Abstract Fusarium is a ubiquitous fungal species found in soil and water. While fusarium can cause localized infection in healthy individuals, it most commonly affects those with compromised immune systems, particularly those with prolonged neutropenia. The morality rate of systemic infection approaches one-hundred percent. Here we present two cases of disseminated fusarium infection in two patients with acute lymphoblastic leukemia (ALL) along with review of literatures regarding prophylaxis and treatment. Key words: Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fusariosis; Case Reports; Immunocompromised Host Case Report ple erythematous to purpuric slightly indu- Patient A was a 45-year-old Caucasian rated papules and plaques scattered on her woman with a history of ALL, 182 days status face, arms, and legs, along with several ten- post stem cell transplant, complicated by der papules and nodules with occasional graft vs. host disease (GVHD) and two relaps- dusky centers on the lower legs (Figure 1). es of her ALL who presented as an urgent Patient B was also a 45-year-old Cauca- consult to dermatology clinic for a one-week sian woman with a history of ALL, 225 days history of rash.
    [Show full text]
  • Tricalcium Phosphate Is Inappropriate As a Universal Selection Factor for Isolating and Testing Phosphate-Solubilizing Bacteria
    Biol Fertil Soils (2013) 49:465–479 DOI 10.1007/s00374-012-0737-7 ORIGINAL PAPER Tricalcium phosphate is inappropriate as a universal selection factor for isolating and testing phosphate-solubilizing bacteria that enhance plant growth: a proposal for an alternative procedure Yoav Bashan & Alexander A. Kamnev & Luz E. de-Bashan Received: 26 June 2012 /Revised: 16 August 2012 /Accepted: 30 August 2012 /Published online: 2 October 2012 # Springer-Verlag 2012 Abstract Literature analysis and chemical considerations Other compounds are also tested, but on a very small of biological phosphate solubilization have shown that the scale. These phosphates (P), mainly Fe-P, Al-P, and commonlyusedselectionfactor for this trait, tricalcium several Ca-P, are even less soluble than TCP in water. phosphate (TCP), is relatively weak and unreliable as a Because soils greatly vary by pH and several chemical universal selection factor for isolating and testing considerations, it appears that there is no metal-P com- phosphate-solubilizing bacteria (PSB) for enhancing plant pound that can serve as the universal selection factor for growth. Most publications describing isolation of PSB PSB. A practical approach is to use a combination of employed TCP. The use of TCP usually yields many (up two or three metal-P compounds together or in tandem, to several thousands per study) isolates “supposedly” PSB. according to the end use of these bacteria—Ca-P com- When these isolates are further tested for direct contribution pounds (including rock phosphates) for alkaline soils, of phosphorus to the plants, only a very few are true PSB. Fe-P and Al-P compounds for acidic soils, and phytates for soils rich in organic P.
    [Show full text]
  • Brochure-Product-Range.Pdf
    PRODUCT RANGE 2015 edition ANSI Standard 60 NSF® CERTIFIED HALAL M ISLAMIC FOOD AND NUTRITION ® COUNCIL OF AMERICA Rue Joseph Wauters, 144 ISO 9001:2008 (Quality) / OHSAS 18001:2007 (Health/ B-4480 Engis Safety) / ISO 14001:2004 (Environment) / ISO 22000:2005 www.globulebleu.com (Food Safety) / FSSC 22000:2013 (Food Safety). Tel. +32 (0) 4 273 93 58 Our food grade phosphates are allergen free, GMO free, Fax. +32 (0) 4 275 68 36 BSE/TSE free. www.prayon.com mail. [email protected] Design by www.prayon.com PRODUCT RANGE | 11 TABLE OF CONTENTS HORTICULTURE APPLICATIONS HORTIPRAY® RANGE FOR HORTICULTURE* FOOD AND INDUSTRIAL APPLICATIONS PRODUCT NAME Bulk density P O pH N-NH Made 2 5 4 MONOAMMONIUM PHOSPHATE - NH4H2PO4 in 3 3 % 1% % Sodium orthophosphates ................................................................................... 03 g/cm lbs/ft indicative indicative indicative Water-soluble fertilisers. Sodium pyrophosphates .................................................................................... 04 HORTIPRAY® MAP Horticultural Grade 0.9 56 61 4.5 12 Sodium tripolyphosphates ................................................................................. 05 HORTIPRAY® MAP 12.60 Horticultural Grade 0.9 56 60 5 12.1 Water-soluble fertilisers; Sodium polyphosphates ..................................................................................... 06 HORTIPRAY® MAP anticalc Horticultural Grade 0.9 56 61 4.5 12 preventive action against clogging. Potassium orthophosphates .............................................................................
    [Show full text]
  • CLINICA CHIMICA ACTA International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine
    CLINICA CHIMICA ACTA International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.1 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.4 ISSN: 0009-8981 DESCRIPTION . Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnosticapplication of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal's scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.
    [Show full text]
  • Lawrence Charles Parish, MD, MD (Hon), Editor-In-Chief
    Lawrence Charles Parish, MD, MD (Hon), Editor-in-Chief Doctor Lawrence Charles Parish received his MD degree from Tufts University School of Medicine, Boston, MA, interned at the Philadelphia General Hospital (Blockley), and was a resident in dermatology at the Hospital of the University of Pennsylvania. He was the first Fellow in Medical Journalism at the Journal of the American Medical Association. He is in the private practice of dermatology in Philadelphia, where is also Clinical Professor of Dermatology and Cutaneous Biology and Director of the Jefferson Center for International Dermatology, Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia. He has served on the faculty of the University of Pennsylvania School of Veterinary Medicine and has been Visiting Professor of Dermatology at Tulane University School of Medicine, New Orleans, LA, Yonsei University College of Medicine, Seoul, Korea, and Zagazig University School of Medicine, Zagazig, Egypt. He has received an honorary degree from the Sofia Faculty of Medicine in Bulgaria. His dermatology interests include decubitus ulcers, tropical dermatology, arthropod infestations, cutaneous bacterial infections, and the history of dermatology, for which he is President of the History of Dermatology Society and Honorary Member of the European Society for the History of Medicine. His list of publications approaches 600 contributions and 60 chapters or books. Doctor Parish is also Editor-in-Chief of SKINmed and former Editor-in-Chief of the International Journal of Dermatology. He serves on the Editorial Board of the Journal of the European Academy of Dermatology and Venereology, Journal of Cosmetic Dermatology, Acta Dermatologica Croatia, and Cutis.
    [Show full text]
  • Searching EMBASE (Elsevier)
    Searching EMBASE (Elsevier) EMBASE description • biomedical and pharmaceutical database • contains all of MEDLINE’s citations and many more unique citations • use when conducting systematic reviews or when searching for information on: food/diet/nutrition, medical devices, or drugs Access EMBASE 1. Go to Ruth Lilly Medical Library Databases. (https://iupui.libguides.com/az.php?s=83627) 2. Scroll down to click on, EMBASE (Elsevier), OR click “E” on the alphabet bar. 3. NOTE: If you are off campus, you will need to enter your university ID and password before you can access this resource. Basic search in EMBASE 1. Identify main concepts. 2. Type terms in the Quick Search Box. 3. Use a single or double quote around a phrase. 4. Use subject headings from EMTREE®. 5. Combine concepts using Boolean operators: AND, OR, NOT Boolean “AND” Boolean “OR” Boolean “NOT” Using AND will retrieve OR will retrieve more NOT will exclude fewer results (ex. heart attacks results (ex. heart attack unwanted terms (ex. AND aspirin) OR myocardial substance abuse NOT infarction) cigarettes). Table 1 Boolean AND, OR, and NOT visualized https://library.mednet.iu.edu/ (317) 274-7182 JCS 5/2020 Results page: Fine-tune your search Filter Results: Beneath the search box: If you click on Quick limits, you will have the options to limit your search to Human subjects and English language. Left-side bar: From most recent search, click each filter to see how many articles are in that subset: e.g. age, gender, drugs used, and other diseases. Work with Search History: • Combine searches using AND; OR • Select any search in History to recall the results.
    [Show full text]
  • Journals 2016 Catalog Directors’ Letter
    MIT Press Journals 2016 catalog Directors’ Letter Dear Friends, The MIT Press celebrated its 50th anniversary in 2012, and the inclination to ponder our distinguished history remains strong, perhaps even more so this year with the change in Press leadership—Amy Brand was named Director of the MIT Press in July of 2015. The Press’s journals division, which was founded in 1972, ten years after the books division, also has a significant publishing legacy to consider, with over 80 journals published since the division’s inception. Some, such as Linguistic Inquiry and The Journal of Interdisciplinary History, have grown with us from the very beginning. Other core titles like International Security, October, The Review of Economics and Statistics and Journal of Cognitive Neuroscience joined the Press over the following decades, providing a solid base for the high-quality and innovative scholarship that our journals division is well known for. Today, we continue to push the boundaries of scholarly publishing and communication. We relish discovering new fields to publish in, and working with scholars who are establishing new domains of research and inquiry. In keeping with that spirit, the Press is proud to launch a new open access journal in 2016, Computational Psychiatry, to serve a burgeoning field that brings together experts in neuroscience, decision sciences, psychiatry, and computation modeling to apply new quantitative techniques to our understanding of psychiatric disorders. Developing new ways of delivering journal articles and providing a richer range of metrics around their usage and impact is another current effort. On our mitpressjournals.org site, the Press is providing Altmetric badges for select titles to give an improved sense of the breadth of a journal article’s reach.
    [Show full text]
  • View Document
    11/07/2017 Embase Select Language ▼ Logout Session Results / Record 4 of 173 Full record Record 4 Similar records | Add to Clipboard | Email Record The utilisation of modern transport and telecommunications platforms to assist in the remote provision of paediatric cancer diagnostics in Tanzania Mcdermott M., O'Hare K., Scanlon P., Grehan D., Rooney S., Laiti R., Kaijage J., Jumanne S., O'Sullivan M. Pediatric Blood and Cancer 2016 63 Supplement 3 (S71) Go to publisher for the full text Abstract Background/Objectives: The acquisition of a pathologic diagnosis represents a critical point in the management of children with malignant disease, allowing staff to plan a therapeutic pathway. In resource poor settings, diagnoses help to identify children who will benefit from the limited interventions available and those who will not. Access to timely diagnoses can be a challenge in low and middle income countries. While enhanced local laboratory capacity is the ultimate answer, interim solutions are needed to assist programs with existing deficits. Modern transport and telecommunications technology can facilitate this process. Design/Methods: Muhimbili University, Dar es Salaam, provides a paediatric cancer program for Tanzania. As part of a formal twinning arrangement, laboratory staff in Dublin have provided interim diagnostic services while helping to develop local paediatric cancer diagnostic capacity in Tanzania. Samples are transported free via DHL® couriers. Preliminary reports are communicated to local clinical staff via WhatsApp with final reports scanned and e-mailed. Results: Since 2008, almost 1000 cancer samples have been transported from Dar to Dublin. Transport time is two working days. In 92% of cases, a preliminary communication regarding specimen adequacy and provisional diagnosis was communicated via WhatsApp the day after receipt.
    [Show full text]
  • Tricalcium Phosphate: an X-Ray Diffraction, Solid State NMR and ATR-FTIR Study
    Journal of Functional Biomaterials Article Strontium and Zinc Substitution in β-Tricalcium Phosphate: An X-ray Diffraction, Solid State NMR and ATR-FTIR Study Elisa Boanini 1 , Massimo Gazzano 2,* , Carlo Nervi 3 , Michele R. Chierotti 3 , Katia Rubini 1, Roberto Gobetto 3 and Adriana Bigi 1 1 Department of Chemistry “Giacomo Ciamician”, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy; [email protected] (E.B.); [email protected] (K.R.); [email protected] (A.B.) 2 ISOF-CNR, via Gobetti 101, 40129 Bologna, Italy 3 Department of Chemistry, University of Torino, via P. Giuria 7, 10125 Torino, Italy; [email protected] (C.N.); [email protected] (M.R.C.); [email protected] (R.G.) * Correspondence: [email protected]; Tel.: +39-051-2099552 Received: 27 March 2019; Accepted: 28 April 2019; Published: 5 May 2019 Abstract: β-tricalcium phosphate (β-TCP) is one of the most common bioceramics, widely applied in bone cements and implants. Herein we synthesized β-TCP by solid state reaction in the presence of increasing amounts of two biologically active ions, namely strontium and zinc, in order to clarify the structural modifications induced by ionic substitution. The results of X-ray diffraction analysis indicate that zinc can substitute for calcium into a β-TCP structure up to about 10 at% inducing a reduction of the cell parameters, whereas the substitution occurs up to about 80 at% in the case of strontium, which provokes a linear increase of the lattice constants, and a slight modification into a more symmetric structure.
    [Show full text]
  • Material Safety Data Sheet
    Material safety data sheet Product name: MSDS date created:Vitoss ™ Scaffold Manufacturer16 June 2021 Australian supplier New Zealand supplier Name: Address: DSM Biomedical Stryker Australia Stryker New Zealand 735 Pennsylvania Drive 8 Herbert St 511 Mt Wellington Highway Phone No: Exton, PA 19341 U.S.A St Leonards NSW Auckland, New Zealand 1060 Fax No: Australia 2065 +484 713-2100 +61 02 9467 1000 +64 09 573 1890 - +61 02 9467 1010 +64 09 573 1891 VITOSS™ SCAFFOLD 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER Product Name Vitoss™ Scaffold Synonym(s) BETA-TCP • CALCIUM PHOSPHATE • CALCIUM PHOSPHATE TRIBASIC • TCP • VITOSS SCAFFOLD Use(s) ORTHOPAEDIC APPLICATIONS Manufacturer Australian Supplier New Zealand Supplier Name: DSM Biomedical Stryker Australia Stryker New Zealand Address: 735 Pennsylvania Drive 8 Herbert St, 511 Mt Wellington Highway, Exton, PA 19341 U.S.A St Leonards, NSW, Auckland, Australia, 2065 New Zealand, 1060 Phone No: +484 713-2100 +61 02 9467 1000 +64 09 573 1890 Fax No: - +61 02 9467 1010 +64 09 573 1891 EMERGENCY - 13 11 26 0800 764 766 Contact Person: Nikin Desai, [email protected] 2. HAZARDS IDENTIFICATION CLASSIFIED AS HAZARDOUS ACCORDING TO HAZARDOUS SUBSTANCES [CLASSIFICATION] REGULATIONS 2001. NOT CLASSIFIED AS HAZARDOUS ACCORDING TO THE SAFEWORK AUSTRALIA CRITERIA. HSNO CLASSIFICATION 6.1E Substances that are acutely toxic. 9.1D Substances that are slightly harmful to the aquatic environment or are otherwise designed for biocidal action. HAZARD STATEMENT H303 May be harmful if swallowed. H401 Toxic to aquatic life. H402 Harmful to aquatic life. H413 May cause long lasting harmful effects to aquatic life.
    [Show full text]